<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="a range of viruses. For example, the viruses included were" exact="hepatitis" post="C virus and hepatitis B virus (Mike Sofia), HIV"/>
 <result pre="For example, the viruses included were hepatitis C virus and" exact="hepatitis" post="B virus (Mike Sofia), HIV and hepatitis B virus"/>
 <result pre="C virus and hepatitis B virus (Mike Sofia), HIV and" exact="hepatitis" post="B virus (David Chu), multiple antiviral projects (Maaike Everts),"/>
 <result pre="be in Porto, Portugal, 11–15 June 2018. Antiviral therapy HIV" exact="hepatitis" post="C virus rhinovirus C Zika virus Introduction This article"/>
 <result pre="spectrum of antiviral research. Gertrude Elion Memorial Award Lecture: Viral" exact="hepatitis" post="– The search for a cure Michael (Mike) J"/>
 <result pre="presented to Michael Sofia by ISAR President, José Esté. Viral" exact="hepatitis" post="is a major, worldwide clinical problem, with about 170"/>
 <result pre="worldwide clinical problem, with about 170 million chronically infected with" exact="hepatitis" post="C virus (HCV) and 350 million with hepatitis B"/>
 <result pre="infected with hepatitis C virus (HCV) and 350 million with" exact="hepatitis" post="B virus (HBV). In the USA, during the period"/>
 <result pre="USA, during the period 1999–2007, the burden of mortality with" exact="viral hepatitis" post="due to HBV had been falling steadily (from six"/>
 <result pre="during the period 1999–2007, the burden of mortality with viral" exact="hepatitis" post="due to HBV had been falling steadily (from six"/>
 <result pre="– African Americans, in cirrhotic patients, in those with decompensated" exact="liver disease" post="and in liver transplant patients. To date, there have"/>
 <result pre="two other herpesviruses, Epstein–Barr virus (EBV, glandular fever/infectious mononucleosis) and" exact="herpes simplex" post="virus type 1 (cold sores). Against these herpesviruses, l-BHDU"/>
 <result pre="important toxicity issue when BVdU and 5-FU were co-administered to" exact="cancer" post="patients. In a VZV animal model, l-BHDU (150 mg/kg)"/>
 <result pre="did not inhibit cell replication at &amp;gt;100 µM. Against woodchuck" exact="hepatitis" post="virus (WHV) in woodchucks (n = 4/group), l-FMAU (clevudine) at various"/>
 <result pre="region of E from dengue, Zika, West Nile and Japanese" exact="encephalitis" post="viruses, the compounds were tested for activity against these"/>
 <result pre="(VP-1, 2, 3 and 4). Following the outbreak of a" exact="severe acute respiratory syndrome," post="which was shown to be caused by a coronavirus"/>
 <result pre="RV-C has been shown to be the primary cause of" exact="asthma" post="exacerbations and viral pneumonia in infants. In a clinical"/>
 <result pre="shown to be the primary cause of asthma exacerbations and" exact="viral pneumonia" post="in infants. In a clinical study, RV-C was detected"/>
 <result pre="to be the primary cause of asthma exacerbations and viral" exact="pneumonia" post="in infants. In a clinical study, RV-C was detected"/>
 <result pre="clinical study, RV-C was detected in 60% of children with" exact="asthma" post="exacerbations versus 24% with either RV-A or RV-B, 14%"/>
 <result pre="CDHR3 was reported to be an important susceptibility gene for" exact="asthma" post="exacerbations, which are one of the most frequent causes"/>
 <result pre="parents (homozygous for Tyr 529), have 5–10-fold higher risk for" exact="asthma" post="exacerbations and hospitalisation than those with only Cys 529"/>
 <result pre="intermediate risk. In this study, the proportions of patients with" exact="asthma" post="were 67, 3 and 29%, respectively. The CDHR3 Tyr"/>
 <result pre="of Wisconsin-Madison. For his postdoctoral fellowship (1984), he studied persistent" exact="measles" post="infections at the Rockefeller University in New York. Currently,"/>
 <result pre="comparison, this mutation rate is faster than that for HIV," exact="influenza" post="viruses and HCV, viruses generally considered to be rapidly"/>
 <result pre="deficiency can lead to prolonged virus shedding (&amp;gt;6 months) but" exact="severe combined immunodeficiency" post="(SCID) and common variable immunodeficiency (CVID) can result in"/>
 <result pre="virus shedding (&amp;gt;6 months) but severe combined immunodeficiency (SCID) and" exact="common variable immunodeficiency" post="(CVID) can result in chronic shedding (&amp;gt;5 years). One"/>
 <result pre="antiviral therapies for flaviviruses, there are some vaccines, for example," exact="yellow fever" post="virus vaccine. This suggests that a vaccine for Zika"/>
 <result pre="study identifies CDHR3 as a susceptibility locus for early childhood" exact="asthma" post="with severe exacerbations . Nat Genet 2014; 46: 51–"/>
 <result pre="27815125 8 Vere Hodge RA Field HJ. Antiviral agents for" exact="herpes simplex" post="virus. Adv Pharmacol 2013; 67: 1– 38. 23885997"/>
</results>
